Gaining ground on a cure through synergy: combining checkpoint inhibitors with cancer vaccines

References

• Ipilimumab [ Updated 2015; cited 2016 Mar 15]. Available from: www.fda.gov.
   Google Scholar
• Nivolumab (Opdivo) [ cited 2016 Mar 15]. Available from: www.fda.gov/drugs.
   Google Scholar
• Pembrolizumab [ cited 2016 Mar 20]. Available from: www.fda.gov/drugs.
   Google Scholar
• Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–330.
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34.
   PubMed Web of Science ®Google Scholar
• John T. Role of immunotherapy in lung cancer: preliminary results of new vaccines and immune checkpoint inhibitors. Asia Pac J Clin Oncol. 2015;11(Suppl 1):2–8.
   PubMed Web of Science ®Google Scholar
• Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res: off J Am Assoc Cancer Res. 2014;20(19):5064–5074.
   PubMed Web of Science ®Google Scholar
• Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–571.
   PubMed Web of Science ®Google Scholar
• Hale DF, Clifton GT, Sears AK, et al. Cancer vaccines: should we be targeting patients with less aggressive disease? Expert Rev Vaccines. 2012;11(6):721–731.
   PubMed Web of Science ®Google Scholar
• Van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med. 1999;190(3):355–366.
   PubMed Web of Science ®Google Scholar
• Karyampudi L, Lamichhane P, Scheid AD, et al. Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody. Cancer Res. 2014;74(11):2974–2985.
   PubMed Web of Science ®Google Scholar
• Soares KC, Rucki AA, Wu AA, et al. PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors. J Immunother. 2015;38(1):1–11.
   PubMed Web of Science ®Google Scholar
• Kleponis J, Skelton R, Zheng L. Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors. Cancer Biol Med. 2015;12:201–208.
   PubMedGoogle Scholar
• Le DT, Lutz E, Uram JN, et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother. 2013;36(7):382–389.
   PubMed Web of Science ®Google Scholar
• Le DT, Wang-Gillam A, Picozzi V, et al. Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol. 2015;33(12):1325–1333.
   PubMed Web of Science ®Google Scholar
• Antonarakis ES, Carducci MA. Combining low-dose cyclophosphamide with GM-CSF-secreting prostate cancer immunotherapy enhances antitumor immune effects. Expert Opin Investig Drugs. 2010;19(2):311–314.
   PubMed Web of Science ®Google Scholar
• Hoffman-Censits JH, Grivas P, Van Der Heijden MS, et al. Imvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC). J Clin Oncol. 2016;34(Suppl 2S): Abstr355
   Google Scholar
• Endo M, De Graaff MA, Ingram DR, et al. NY-ESO-1 (CTAG1B) expression in mesenchymal tumors. Modern Pathol: Off J United States Canadian Acad Pathol, Inc. 2015;28(4):587–595.
   PubMed Web of Science ®Google Scholar
• Pipeline: CMB305 [ cited 2016 Mar 15]. Available from: www.immunedesign.com/pipeline.
   Google Scholar
• Raez L, Walker GR, Baldie P, et al. CD8 T cell response in a phase I study of therapeutic vaccination of advanced NSCLC with allogeneic tumor cells secreting endoplasmic reticulum-chaperone gp96-Ig-peptide complexes. Adv Lung Cancer. 2013;2(1):9–18.
   Google Scholar
• Dhodapkar MV, Sznol M, Zhao B, et al. Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Sci Transl Med. 2014;6(232):232ra51.
   PubMed Web of Science ®Google Scholar
• Wang J, Yu L, Jiang C, et al. Cerebral ischemia increases bone marrow CD4+CD25+FoxP3+ regulatory T cells in mice via signals from sympathetic nervous system. Brain Behav Immun. 2015;43:172–183.
   PubMed Web of Science ®Google Scholar
• Tang SC, Montero A, Munn D, et al. A phase 2 randomized trial of the IDO pathway inhibitor indoximod in combination with taxane based chemotherapy for metastatic breast cancer: preliminary data. Cancer Res. 2016;76(Suppl 4): Astractnr P2-11-09.
   Google Scholar
• Ou X, Cai S, Liu P, et al. Enhancement of dendritic cell-tumor fusion vaccine potency by indoleamine-pyrrole 2,3-dioxygenase inhibitor, 1-MT. J Cancer Res Clin Oncol. 2008;134(5):525–533.
   PubMed Web of Science ®Google Scholar
• Soliman HH, Minton SE, Han HS, et al. A phase I study of ad.p53 DC vaccine in combination with indoximod in metastatic solid tumors. J Clin Oncol. 2013;31((Suppl):Abstr 3069).
   PubMed Web of Science ®Google Scholar
• Non-small Cell Lung Cancer. [ cited 2016 Mar 15]. Available from: www.newlinkgenetics.com/platforms/hyperacute-immunotherapies.
   Google Scholar
• Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009;115(16):3670–3679.
   PubMed Web of Science ®Google Scholar
• Madan RA, Mohebtash M, Arlen PM, et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13(5):501–508.
   PubMed Web of Science ®Google Scholar
• Madan RA, Arlen PM, Mohebtash M, et al. Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs. 2009;18(7):1001–1011.
   PubMed Web of Science ®Google Scholar
• Singh H, Madan RA, Dahut WL, et al. Combining active immunotherapy and immune checkpoint inhibitors in prostate cancer. J Clin Oncol. 2015;33(Suppl 7): Abstr 172.
   Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723.
   PubMed Web of Science ®Google Scholar
• Wilgenhof S, Van Nuffel AMT, Benteyn D, et al. A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. Ann Oncol. 2013;24(10):2686–2693.
   PubMed Web of Science ®Google Scholar
• Wilgenhof S, Corthals J, Heirman C, et al. Phase II study of autologous monocyte-derived mRNA electroporated dendritic cells (TriMixDC-MEL) plus ipilimumab in patients with pretreated advanced melanoma. J Clin Oncol. 2016;34(12):1330–1338.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced malanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11:155–164.
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. New Engl J Med. 2011;364:2517–2526.
   PubMed Web of Science ®Google Scholar
• Hu Y, Kim H, Blackwell CM, et al. Long-term outcomes of helper peptide vaccination for metastatic melanoma. Ann Surg. 2015;262(3):456–464. discussion 62-4
   PubMed Web of Science ®Google Scholar
• Greene JM, Schneble EJ, Jackson DO, et al. A phase I/IIa clinical trial in stage IV melanoma of an autologous tumor-dendritic cell fusion (dendritoma) vaccine with low dose interleukin-2. Cancer Immunol, Immunother: CII. 2016;65(4):383–392.
   PubMed Web of Science ®Google Scholar
• Herbert GS, Greene JM, Jackson DO, et al. Initial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumors. J Clin Oncol. 2016 (supply; Abstr 3089).
   Google Scholar
• Jackson DO, Green J, Hale DF, et al. Preclinical testing of a novel personalized cancer vaccine for all solid tumors and all patients. J Immunother Cancer. 2015;3(Suppl 2):P208.
   Google Scholar